Journal Article Ppublish 2 citations
PubMed: 39503428 DOI: 10.4103/NRR.NRR-D-24-00659
Syndecans in Alzheimer's disease: pathogenetic mechanisms and potential therapeutic targets.
Neural Regen Res 20(9):2594-2595
Authors: Carmela Rita Balistreri, Roberto Monastero
Affiliations
- Cellular, Molecular and Clinical Pathological Laboratory, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, Palermo, Italy (Balistreri CR).
- Memory and Parkinson's disease Center, Policlinico "Paolo Giaccone", Palermo; Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, Via La Loggia 1, Palermo, Italy (Monastero R).
MeSH
Alzheimer Disease, Syndecans, Therapeutics
Cited by
- Local and Systemic Endothelial Damage in Patients with CEAP C2 Chronic Venous Insufficiency: Role of Mesoglycan. Int J Mol Sci, 2025
- Shed Syndecans (1-3), ELA-32, BDNF, NLR, and hs-CRP in Parkinson's Disease: Appropriate Diagnostic and Prognostic Biomarkers When Combined in a Unique Panel. Int J Mol Sci, 2025